|
MechanismSGPL1 inhibitors |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey Disease - DERM-101
100 Clinical Results associated with Dermecular Therapeutics, Inc.
0 Patents (Medical) associated with Dermecular Therapeutics, Inc.
100 Deals associated with Dermecular Therapeutics, Inc.
100 Translational Medicine associated with Dermecular Therapeutics, Inc.